CN119053337A - 癌症疫苗及其使用方法 - Google Patents

癌症疫苗及其使用方法 Download PDF

Info

Publication number
CN119053337A
CN119053337A CN202380034852.XA CN202380034852A CN119053337A CN 119053337 A CN119053337 A CN 119053337A CN 202380034852 A CN202380034852 A CN 202380034852A CN 119053337 A CN119053337 A CN 119053337A
Authority
CN
China
Prior art keywords
hla
allele
cancer cell
gene
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380034852.XA
Other languages
English (en)
Chinese (zh)
Inventor
威廉·V·威廉姆斯
米格尔·洛佩兹-拉戈
马库斯·丹尼尔·拉彻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Briacell Therapeutics Corp USA
Original Assignee
Briacell Therapeutics Corp USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Briacell Therapeutics Corp USA filed Critical Briacell Therapeutics Corp USA
Publication of CN119053337A publication Critical patent/CN119053337A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380034852.XA 2022-03-03 2023-03-02 癌症疫苗及其使用方法 Pending CN119053337A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263316251P 2022-03-03 2022-03-03
US63/316,251 2022-03-03
US202263415475P 2022-10-12 2022-10-12
US63/415,475 2022-10-12
PCT/US2023/014337 WO2023167973A1 (en) 2022-03-03 2023-03-02 Cancer vaccines and methods of use thereof

Publications (1)

Publication Number Publication Date
CN119053337A true CN119053337A (zh) 2024-11-29

Family

ID=85772911

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380034852.XA Pending CN119053337A (zh) 2022-03-03 2023-03-02 癌症疫苗及其使用方法

Country Status (8)

Country Link
US (1) US20250186568A1 (https=)
EP (1) EP4486371A1 (https=)
JP (1) JP2025507939A (https=)
CN (1) CN119053337A (https=)
AU (1) AU2023227477A1 (https=)
CA (1) CA3254024A1 (https=)
IL (1) IL315361A (https=)
WO (1) WO2023167973A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240156869A1 (en) * 2021-03-12 2024-05-16 T-Cure Bioscience, Inc. Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy
WO2025171109A1 (en) 2024-02-07 2025-08-14 Briacell Therapeutics Corp. Cancer vaccines expressing post-translational modified antigens and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858776A (en) * 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
DE19832840C1 (de) * 1998-07-21 2000-06-08 Kerkmann Tucek Aida Mittel zur Immuntherapie von Tumorerkrankungen
US7807186B2 (en) * 2007-01-17 2010-10-05 University Of Maryland, Baltimore County Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines
WO2017147600A1 (en) 2016-02-25 2017-08-31 Briacell Therapeutics Corp. Whole-cell cancer vaccines and methods for selection thereof

Also Published As

Publication number Publication date
AU2023227477A1 (en) 2024-09-19
IL315361A (en) 2024-11-01
US20250186568A1 (en) 2025-06-12
JP2025507939A (ja) 2025-03-21
EP4486371A1 (en) 2025-01-08
WO2023167973A1 (en) 2023-09-07
CA3254024A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
Tsimberidou et al. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors
AU2020201896B2 (en) Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
EP3885357B1 (en) Interleukin 21 protein (il21) mutant and use thereof
CA3104034A1 (en) Nanoparticles for gene expression and uses thereof
CN115551537A (zh) 肿瘤细胞疫苗
TW202206453A (zh) 表現嵌合抗原受體之病毒特異性免疫細胞
JP2019510488A (ja) 抗腫瘍免疫を誘導するための、腫瘍関連抗原の複数のエピトープを発現するウイルスベクター
CA3223546A1 (en) Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
JP2017502029A (ja) ネオ抗原ワクチンによる併用療法
AU2018219862B2 (en) Maximizing T-cell memory and compositions and methods therefor
US20250186568A1 (en) Cancer vaccines and methods of use thereof
JP2022553192A (ja) 癌ワクチン
KR20230069956A (ko) 이종 프라임 부스트 백신
US20240376429A1 (en) Virus-specific immune cells expressing chimeric antigen receptors
HK40117271A (zh) 癌症疫苗及其使用方法
EP4522207A1 (en) Individualized cancer epitopes and methods of using the same
Lasek et al. Interleukin 12: Antitumor activity and immunotherapeutic potential in oncology
WO2025171109A1 (en) Cancer vaccines expressing post-translational modified antigens and methods of use thereof
AU2024246543A1 (en) Methods for enhancing the immunogenicity of cellular vaccines
KR20260051061A (ko) Cd19-표적화 car t 세포 요법
KR20250024750A (ko) 치료용 t 세포 산물
Spear Endogenous Leukocyte Activation by Chimeric Antigen Receptor T cell Immunotherapy
HK40015270B (zh) Hla限制性vgll1肽及其用途
NZ735850B2 (en) Claudin-18.2-specific immunoreceptors and t cell epitopes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40117271

Country of ref document: HK